{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-199931","form_type":"8-K","ticker":"STIM","cik":"0001227636","company_name":"Neuronetics, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.387107+00:00","generated_at":"2026-05-31T09:16:01.394152+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"medium","headline":"Neuronetics announces FDA clearance for NeuroStar add-on therapy for ages 15 and older","bullets":["FDA cleared NeuroStar Advanced Therapy System as an add-on treatment for patients aged 15 and older.","Management targets cash flow break-even in Q4 2024 and on a full-year basis in 2025.","Proposed combination with Greenbrook TMS Inc. remains ongoing; stockholder approval pending.","Company presenting at William Blair 44th Annual Growth Stock Conference on August 14, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-199931","json":"https://secwatch.observer/filing/0001193125-24-199931.json","markdown":"https://secwatch.observer/filing/0001193125-24-199931.md","text":"https://secwatch.observer/filing/0001193125-24-199931.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1227636/000119312524199931/0001193125-24-199931-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1227636/000119312524199931/d835019d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:16:01.394152+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}